Ganzhou Hemay Pharmaceutical Co., Ltd
Last updated Jun 17, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
1
Clinical Programs
0
Confidence Coverage
72%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Gastroenterology
- Ulcerative Colitis
Highest priority development: Opportunities for patients and the public to be involved in the work of the MHRA
Regulatory precedent
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Ganzhou Hemay Pharmaceutical Co., Ltd.
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 72%
Active Signals
1
Investigate Priority
0
Opportunity Score
16
Buyer Quality
7 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 17, 2026Score 16Phase III Trial of Hemay005 in Chinese Patients with Ulcerative Colitis Initiated
Gastroenterology · Ulcerative Colitis
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Opportunities for patients and the public to be involved in the work of the MHRAModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)MHRAMHRARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Ganzhou Hemay Pharmaceutical Co., Ltd right now?
- Which regulatory precedents should Ganzhou Hemay Pharmaceutical Co., Ltd monitor in Gastroenterology and Ulcerative Colitis?
- How does Duvakitug's Phase 3 Study Initiation compare to the nearest competitive programs?
- What signals require immediate investigation for Ganzhou Hemay Pharmaceutical Co., Ltd?
- Summarize the strategic implications of recent developments for Ganzhou Hemay Pharmaceutical Co., Ltd.
- Where is the greatest uncertainty in Ganzhou Hemay Pharmaceutical Co., Ltd's competitive positioning?